NeuroPace (NPCE) said late Monday that it expects "minimal impact" to its operations and financial results from the Trump administration's tariffs .
The medical device company said it manufactures and sells the "vast majority" of its devices in the US and has "limited" supply chain activities outside the country for its responsive neurostimulation System.
The firm expects "no material" impact on gross margin for DIXI Medical SEEG products.
It expects "minimal impact" to gross margin for fiscal 2025 and is reiterating its gross margin guidance for 2025.
NeuroPace will report Q1 financial results after market close on May 13.